Updated on 10 March 2014
DCGI’s statement said that the report made some “baseless, irresponsible and malicious” claims by stating that WHO estimates that one in five drugs made in India is a fake
Singapore: The public information cell of the Drugs Controller General of India has issued a statement contradicting a New York Times report that claimed that ‘India-made drugs trigger safety concerns in US'.
DCGI's statement said that the report made some "baseless, irresponsible and malicious" claims by stating that WHO estimates that one in five drugs made in India is a fake.
The report further added that WHO had clarified as recently as on August 31, 2012 that there was no such study carried out by the WHO. "They have also regretted that occasionally some individuals in the media and the organizations use WHO references incorrectly and even irresponsibly," the release said.
The report added that a section of the print media - Indian as well as foreign - has been publishing "factually incorrect and largely unsubstantiated" news "to malign the well-earned reputation of the Indian pharmaceutical industry".
India exports around $15 billion of pharma products, including vaccines to most of the countries in the world. There are about 360 USFDA-approved drug manufacturing units in the country. There are also over 150 European Directorate for the Quality of Medicines (EDQM)-approved drug manufacturing units. As recently as 2013, the WHO has declared the Indian national regulatory authority functional for vaccines against stringent international parameters.